

COMMENT & CONTROVERSY

HAVE A COMMENT TO SHARE? SEND AN EMAIL TO OBG@DOWDENHEALTH.COM

"Give a uterotonic routinely during the third stage of labor," by Robert L. Barbieri, MD (Editorial, May)

Uterotonic, yes, but have a sonogram on file

I agree with Dr. Barbieri's assertion that a uterotonic should be given routinely in the third stage of labor, but I recommend one very important proviso: A sonogram should be on file.

My advice comes from experience. I once took care of an unregistered patient who had not had prenatal care and who came in with cervical dilation to 8 cm and was progressing rapidly. After delivery, I did a digital exam and discovered an undiagnosed twin (vertex). Just think what would have happened if I had given a "routine bolus" of oxytocin!

I trained with people who gave oxytocin when the anterior shoulder was delivered. I have found that the cervix can close down very fast if the uterotonic is given after the baby is delivered but before placental delivery.

John Lewis, MD
Avon, Conn

Dr. Barbieri responds:

Uterotonic can wait until delivery of the placenta

I appreciate Dr. Lewis' astute clinical comments about administering a uterotonic at delivery, which are clearly based on significant clinical experience. In the case of multiple gestation, it is preferable to wait until both fetuses are born before giving a bolus of oxytocin. The undiagnosed multifetal gestation presents a significant challenge for the obstetrician.

Many clinicians have noted that administration of oxytocin after the delivery of the infant's anterior shoulder stimulates cervical contraction and may increase the rate of retained placenta. In response, these clinicians prefer to administer a uterotonic after delivery of the placenta. This practice is perfectly acceptable and has been demonstrated to reduce the risk of postpartum hemorrhage.¹

Reference

1. Nordstrom L, Fogelstam K, Fridman G, Larsson A, Rydhstroem H. Routine oxytocin in the third stage of labour: a placebo controlled randomized trial. *Br J Obstet Gynaecol.* 1997;104:781-786.



"Administration of oxytocin after delivery of the infant's anterior shoulder stimulates cervical contraction and may increase the rate of retained placenta"

"Malpractice risk management: Avoid these common errors in self-defense!" by Claudia Dobbs, MA (April)

Access to prenatal records should be instantaneous

Minimal compliance with an antiquated American College of Obstetricians and Gynecologists (ACOG) guideline to send prenatal records at least once to the hospital by 36 weeks' gestation is NOT "an excellent practice," as suggested by Claudia Dobbs. Such a practice often means that our highest-risk patients—those 12% of births that are preterm—will likely be managed without any prenatal records, especially on nights and weekends. For the rest of our patients, this obsolete tradition leads to the commonplace scenario in which patients are managed with incomplete, outdated records—or none at all.

Risk managers and policy makers should insist that complete and up-to-date prenatal records be made available within

Citracal® Prenatal 90+DHA

Rx Prenatal Vitamin Tablet and 250 mg DHA Capsule

DESCRIPTION: Citracal® Prenatal 90+DHA is a prescription prenatal/postnatal multivitamin/mineral tablet and a capsule of an essential fatty acid. The prenatal vitamin is a scored, white, oval multivitamin/mineral tablet. The tablet is embossed "CITRACAL" on one side and "PN 90" on the other. The essential fatty acid DHA capsule is clear and contains an amber to light/ dark orange semi-solid mixture.

Each prenatal tablet contains:

Vitamin A (as Palmitate and beta-carotene)	2700 IU
Vitamin C (Ascorbic acid)	120 mg
Calcium (Calcium citrate)	200 mg
Iron (Carbonyl iron)	90 mg
Vitamin D3 (Cholecalciferol)	400 IU
Vitamin E (dl-alpha tocopheryl acetate)	30 IU
Thiamin (Vitamin B1)	3 mg
Riboflavin (Vitamin B2)	3.4 mg
Niacinamide (Vitamin B3)	20 mg
Vitamin B6 (Pyridoxine HCl)	20 mg
Folic Acid	1 mg
Vitamin B12 (Cyanocobalamin)	12 mcg
Iodine (Potassium iodide)	150 mcg
Zinc (Zinc oxide)	25 mg
Copper (Cupric oxide)	2 mg
Docusate sodium	50 mg

Each DHA gelatin capsule contains:

Docosahexaenoic Acid (DHA) 250 mg
DHA is contained in the oil derived from microalgae.
Other ingredients in DHA gelatin capsule: Gelatin, Glycerin USP, Water.

INDICATIONS: Citracal® Prenatal 90+DHA is a multivitamin/mineral prescription drug indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers. Citracal® Prenatal 90+DHA can also be beneficial in improving the nutritional status of women prior to conception.

CONTRAINDICATIONS: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

WARNING: Ingestion of more than 3 grams of omega-3 fatty acids per day has been shown to have potential antithrombotic effects, including an increased bleeding time and INR. Administration of omega-3 fatty acids should be avoided in patients on anticoagulants and in those known to have an inherited or acquired bleeding diathesis.

WARNING: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B₁₂ is deficient.

PRECAUTIONS: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

CAUTION: Exercise caution to ensure that the prescribed dosage of DHA does not exceed 1 gram (1000 mg) per day.

DOSAGE AND ADMINISTRATION: One tablet and one capsule daily or as directed by a physician.

Store at controlled room temperature.

NOTICE: Contact with moisture can discolor or erode the tablet.

HOW SUPPLIED: Six child-resistant blister packs of 5 tablets and 5 capsules each - NDC 0178-4200-30

U.S. Patent 6,818,228

MISSION PHARMACAL COMPANY

San Antonio, TX 78230 1355

PRE-07202

Rev 010060

Trademark of Martek Biosciences Corporation

U.S. Patent No. 5,407,957

U.S. Patent No. 5,492,938



COMMENT & CONTROVERSY

CONTINUED

seconds to clinicians in labor and delivery, 24 hours a day, 7 days a week, and at any gestational age.

Ms. Dobbs' "helpful hint" and ACOG's current guideline should no longer be condoned or even tolerated in 2007, when effective digital solutions exist that eliminate uninformed labor-and-delivery care forever.

Donald W. Miller Jr, MD
Shawnee, Kan

Ms. Dobbs responds:

Only a few OBs can send records "within seconds"

I applaud Dr. Miller for promoting ideal communication between treating physicians to ensure safe patient care. His comments certainly demonstrate

why physicians should seriously consider interoperable electronic medical records (EMRs). Unfortunately, his recommendations are feasible for only a small minority of physicians. Many of the obstetricians surveyed by my organization's Loss Prevention Department report that they forward their prenatal records within the last trimester, as near to the esti-

estimated delivery date as possible. Very few doctors have EMRs and digitalized prenatal forms, and fewer still are interoperable with the local hospital's EMR system, so their ability to send information digitally is limited. They certainly cannot forward their records "24 hours a day, 7 days a week" or make them available "within seconds," especially on weekends or after hours.

To promote patient safety and decrease physician liability, I maintain that, if a treating obstetrician periodically forwards up-to-date copies of the patient's prenatal records to the labor-and-delivery unit, the delivering obstetrician will have information available at the time of delivery. If the treating obstetrician discusses high-risk patients with his or her on-call colleagues and documents the discussions, the delivering physician will be informed and the treating obstetrician's risk will therefore be reduced.

Preterm delivery is certainly a difficult matter. I really hope that the patient's treating obstetrician is handling these cases personally and not relying on an on-call OB (nights, weekends) to do so without counsel.

CONTINUED





Have you visited
obgmanagement.com
this week? 

Stop by and see how we've filled
our electronic pages with exclusive
advice on clinical and practice
management topics, including

- podcasts (now playing: long-term reversible contraception)
- webcasts (hormone tx for symptomatic menopausal women)
- opportunities to learn while earning no-cost CME credits
- a library of surgical-technique video clips
- bonus reading from the Medical Verdicts department (and other articles and sections)
- a range of supplements and newsletters
- a sign-up option to receive alerts about new features and an early look at every issue's table of contents
- the opinions of your peers—and your vote—in the Instant Poll

Of course, past articles are still there for you—as convenient, downloadable pdf files

And you'll find the easiest way to contact the editorial board and editors with your suggestions and questions



COMMENT & CONTROVERSY

CONTINUED

"Adnexal masses in pregnancy," by Mitchel S. Hoffman, MD, and Robyn A. Sayer, MD (March)

Some anesthesiologists prefer regional anesthesia in pregnancy

I appreciate the information offered by Dr. Hoffman and Dr. Sayer regarding the management of adnexal masses in pregnancy. I have encountered resistance to laparoscopy in pregnant patients from anesthesiologists, who would often prefer laparotomy under regional anesthesia to the general anesthesia required for laparoscopy.

Have the authors encountered this problem?

Eric Rothschild, MD
Fort Lauderdale, Fla

Dr. Hoffman and Dr. Sayer respond:

Large series support safety of general anesthesia

We have encountered the same concern from some anesthesiologists at our institution regarding the use of general anesthesia for elective surgery during the first trimester of pregnancy.

The teratogenicity noted in animal studies and anecdotal reports has not been observed in large case series. Most of our anesthesiologists administer general anesthesia in this setting, but avoid certain agents (eg, nitrous oxide).

Please take a moment to share your opinion!

We want to hear from you!

Have a comment on an article, editorial, illustration, or department? Drop us a line and let us know what you think. **You can send a letter in any of 3 ways:**

Letters should be addressed to the Editor, OBG Management, and be 200 words or less. They may be edited prior to publication.

- 1 **E-mail**
obg@dowdenhealth.com
- 2 **Fax**
201-391-2778
- 3 **Mail**
OBG Management
110 Summit Ave
Montvale, NJ 07645